The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2014

Filed:

Dec. 10, 2009
Applicants:

Zheng Liu, Shanghai, CN;

Jianfeng LI, Shanghai, CN;

Xiaojun Yang, Shanghai, CN;

Zhen Wang, Shanghai, CN;

Jinfeng Zhang, Shanghai, CN;

Yi Zhu, Shandong, CN;

Guanghui Tian, Shanghai, CN;

Qing Jin, Shanghai, CN;

Jingkang Shen, Shanghai, CN;

Weiliang Zhu, Shanghai, CN;

Hualiang Jiang, Shanghai, CN;

Jingshan Shen, Shanghai, CN;

Inventors:

Zheng Liu, Shanghai, CN;

Jianfeng Li, Shanghai, CN;

Xiaojun Yang, Shanghai, CN;

Zhen Wang, Shanghai, CN;

Jinfeng Zhang, Shanghai, CN;

Yi Zhu, Shandong, CN;

Guanghui Tian, Shanghai, CN;

Qing Jin, Shanghai, CN;

Jingkang Shen, Shanghai, CN;

Weiliang Zhu, Shanghai, CN;

Hualiang Jiang, Shanghai, CN;

Jingshan Shen, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/54 (2006.01); A61K 31/505 (2006.01); C07D 239/02 (2006.01); C07D 401/12 (2006.01); C07D 417/12 (2006.01); C07D 409/12 (2006.01); C07D 239/36 (2006.01); C07D 405/12 (2006.01); C07D 403/12 (2006.01); C07H 15/26 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); C07D 401/12 (2013.01); C07D 417/12 (2013.01); C07D 409/12 (2013.01); C07D 239/36 (2013.01); C07D 405/12 (2013.01); C07D 403/12 (2013.01); C07H 15/26 (2013.01);
Abstract

The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.


Find Patent Forward Citations

Loading…